logo
What My Two 98 Year Old Patients Taught Me About Longevity

What My Two 98 Year Old Patients Taught Me About Longevity

Meet my patient Mrs. L. R. She's 98 years young and has never suffered a day of serious illness in her long life. She was referred to me by her primary care physician to assess her heart condition because she had developed swelling in her legs, known as edema. When we first met in the clinic, I noted there was no accompanying family member, so I asked how she got to the medical center. She'd driven herself. I soon learned much more about this exceptionally vibrant, healthy lady who lives alone, has an extensive social network, and enjoys her solitude.
Her remarkable health span isn't shared by her family members. Her mother died at 59; her father at 64. Her two brothers died at 43 and 75. Three years prior to our meeting, her husband had died at 97. He had also been quite healthy, with a similar health span profile in contrast to his parents and siblings, who all had chronic diseases and died decades younger. Following her husband's death, Mrs. L. R. got depressed and dropped 30 pounds. She lost her interest in her hobbies of painting and doing 1,000-piece jigsaw puzzles. She did continue to play cards and Rummikub every week with a circle of eight women. One of these friends suggested she move from the house she'd lived in for decades to a senior residence apartment. The move led her to artists, new friends, and an extended social network. This all brought her back to her 'old' self, fully restoring her life's passions and getting back to a healthy weight.
The consultation needed to determine why she had some leg edema. Although she had no history of high blood pressure, her heart was thickened on my echocardiogram and her heart muscle function was well beyond the normal range. Her ejection fraction, the proportion of blood squeezed out of the main pumping chamber with each beat, was abnormally high. I diagnosed hypertrophic cardiomyopathy. Her heart had become stiffened and had difficulty relaxing. This accounted for the leg edema, the treating of which was straightforward and was cleared within a few days. Mrs. L. R. exemplifies healthy aging. She is the unusual individual who has escaped all the common age-related diseases, defying what most of us expect from the human aging process. Her extreme health span and longevity, as well as her husband's, do not appear to be related to genetic makeup. Medical scientists don't understand it, but they would conclude, from all we know about the biology of aging and process of elimination, that it's stochastic, a random stroke of good fortune.
In marked contrast, let me briefly introduce Mr. R. P., another patient whom I have followed for over 30 years, who is now also 98 and led a relatively healthy lifestyle. At 75, following coronary artery bypass surgery at 62, Mr. R. P. presented with chest pain with exertion. At the time, I placed two stents in one of his bypass grafts that had developed blockages, which stem from buildup of atherosclerosis that limits blood flow. He later developed rapid atrial fibrillation resistant to medications and underwent two ablation procedures to maintain a normal heart rhythm.
Years later, he had a shoulder replacement and sustained a small heart attack post-operatively. At 96, he was hospitalized with COVID-19 pneumonia and, despite a prolonged hospitalization, did not develop respiratory failure and fully recovered. Mr. R. P. represents the triumphs of modern medicine. He had severe atherosclerotic cardiovascular disease, but with repeated restoration of blood supply to his heart and aggressive secondary prevention treatment, all was well. He embodies the medical progress we've made with age-related diseases.
What's exciting now is that we can accurately forecast heart disease as well as the other major diseases of aging in high-risk individuals many decades earlier and achieve primary prevention, or, at the very least, a marked delay in their appearance. Doctors can't promise to reverse or halt aging itself, but we can promise that the second half of our lives can be much healthier than that of our forebears. This is the type of health span extension that we will be seeing far more commonly in the future owing to the phenomenal advances in lifestyle, cells, genomics, artificial intelligence, drugs, and vaccines. These dimensions all interact with one another: Our lifestyle factors influence our microbiome and cells. Our response to drugs and vaccines is modulated by our genomics and cells, and discovery of new drugs has been enhanced by gene variants and by AI.
There are still formidable obstacles—including profound health inequity across the U.S.—but as we move forward, we will inevitably see suppression of age-related diseases that for many is unimaginable right now. It will take years to accomplish the far bolder objective of slowing the aging process itself. But when we do, super agers like Mrs. L. R. and Mr. R. P. will seem like an ordinarily vibrant group of people making valuable contributions to society. I recently turned 70, and I am hopeful that you and I will be among them.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Indraprastha Gas shares jump over 2% as Delhi govt set to reviews EV policy
Indraprastha Gas shares jump over 2% as Delhi govt set to reviews EV policy

Business Upturn

time6 minutes ago

  • Business Upturn

Indraprastha Gas shares jump over 2% as Delhi govt set to reviews EV policy

By Aman Shukla Published on June 16, 2025, 10:42 IST Shares of Indraprastha Gas Ltd (IGL) jumped over 2% in early trade after reports emerged that the Delhi government is set to review the Motor Vehicle Aggregator and Delivery Service Provider Scheme, which was introduced in November 2023 by the previous AAP-led administration. As per a report by Hindustan Times , the Delhi Motor Vehicle Aggregator and Delivery Service Provider Scheme—initially introduced in November 2023 under the previous AAP administration—is now being re-evaluated by the transport department. The revision may address concerns from aggregators, gig workers, and consumers, and could include a cap on surge pricing and a more gradual shift to EVs. Transport Minister Pankaj Singh told the Hindustan Times on Tuesday that the government is revisiting key provisions to ensure the policy accommodates aggregators, gig workers, and commuters. Chief Minister Rekha Gupta also confirmed the policy is under review as part of a broader regulatory assessment. Indraprastha Gas shares opened at ₹198.79 and reached a high of ₹204.25 during the session, while the low was ₹198.13. The stock continues to trade within a broad range, with its 52-week high at ₹285.18 and a 52-week low of ₹153.05. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection
Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection

Business Upturn

time6 minutes ago

  • Business Upturn

Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection

By Aman Shukla Published on June 16, 2025, 09:33 IST Natco Pharma shares fell 2% in early trade after the company announced that the U.S. Food and Drug Administration (US FDA) concluded a routine inspection at its API (Active Pharmaceutical Ingredients) facility in Mekaguda, Hyderabad, with one observation. As of 9:32 AM, the shares were trading 2.59% lower at Rs 889.10. The inspection was carried out over five days, from June 9 to June 13, 2025. In an exchange filing, Natco stated that it received a single Form 483 observation, which it described as procedural in nature. The company expressed confidence in addressing the issue promptly and thoroughly. 'The observation is procedural in nature, and the company is confident of addressing it comprehensively,' Natco said in a statement, reaffirming its commitment to maintaining high compliance standards. The Mekaguda facility plays a key role in Natco's API production for global markets. The company reiterated its focus on adhering to current Good Manufacturing Practices (cGMP) and continuing the supply of high-quality pharmaceutical products. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Why are Tata Motors shares falling nearly 5% today? Know More
Why are Tata Motors shares falling nearly 5% today? Know More

Business Upturn

time6 minutes ago

  • Business Upturn

Why are Tata Motors shares falling nearly 5% today? Know More

By Aditya Bhagchandani Published on June 16, 2025, 09:42 IST Shares of Tata Motors Ltd plunged over 4.6% to ₹679.15 on Monday, June 16, after Jaguar Land Rover (JLR) issued a weaker-than-expected financial outlook for FY26 during its latest investor presentation. The stock opened lower and continued to slide, touching an intraday low of ₹679.10. Tata Motors' UK-based luxury car subsidiary JLR stated that it now expects its EBIT margin for FY26 to be in the range of 5–7%, down sharply from the earlier guidance of 10%. This comes as a disappointment to investors, particularly as the company had reported a strong EBIT margin of 10.7% in Q4FY25. In addition to the margin downgrade, JLR said it anticipates free cash flow to be close to zero in FY26, although it expects year-on-year improvement in FY27 and FY28. The update has raised concerns about the near-term profitability and cash generation of the company's luxury vehicle arm, which has been a key driver of growth in recent quarters. At 9:40 AM, Tata Motors' stock was trading at ₹679.15, down 4.62% from the previous close of ₹712.05. The company's market capitalization stood at ₹2.51 lakh crore. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store